Session 6: Differences in strength of association across racial/ancestral groups
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Steven Lewitzky, Novartis, Switzerland Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:25:32More inScience Technology
See the original post here:
Session 6: Differences in strength of association across racial/ancestral groups - Video
Drug Clearance - Pharmacokinetics Lect 12
This lecture covers drug clearance. View the other videos on pharmacokinetics below. (1) Pharmacokinetics Core concepts: youtu.be ---- DRUG ABSORPTION Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:1 0ratingsTime:10:36More inEducation
View original post here:
Drug Clearance - Pharmacokinetics Lect 12 - Video
Advances In Schizophrenia Research 2009
ll4.me Advances In Schizophrenia Research 2009 Incidence and outcome of schizophrenia across the globe.- Gene and environment interactions and epigenetics of schizophrenia.- The course and outcome of schizophrenia: are there new trends?- Impact of contextual mechanisms on the incidence of schizophrenia and other psychoses.- Perspectives and conclusions.- Glutamate-dopamine interactions in schizophrenia.- Schizophrenia: Neurodevelopmental, neurodegenerative or both?.- The neuropathology of schizophrenia: novel findings and epigenetic regulation.- Molecular neuroimaging, pathophysiological mechanisms and drug discovery.- Discussant.- Molecular genetics of schizophrenia: new discoveries and controversies.- Genetic and developmental animal models of schizophrenia.- Neuroproteomic studies of post-mortem brains in schizophrenia.- Neuroimaging studies of gene effects in the brain in schizophrenia.- Pharmacogenomics in schizophrenia.- Perspectives and conclusions.- Prediction of psychosis through the prodromal syndrome.- Is schizophrenia a cognitive disorder?- Disorder of social cognition .- Impact of new strategies (early intervention, second-generation drugs) on the course and outcome of schizophrenia.- Perspectives and conclusions.- Dimensional dysfunctions.- Risk factors for psychosis all impact on dopamine.- Cannabis: clue or distraction?.- The totality of psychosis.- Perspectives and conclusionst.- Comparative efficacy and safety of second-generation antipsychotics: facts ...From:lorrainephilips754Views:0 0ratingsTime:00:11More inPeople Blogs
Read this article:
Advances In Schizophrenia Research 2009 - Video
One TEST, One right ANSWER, 1PGx Pharmacogenomics
Testing your genetic background finding the right drug for the right patient, the right dosage right now!From:miketerry3Views:0 0ratingsTime:06:20More inPeople Blogs
Excerpt from:
One TEST, One right ANSWER, 1PGx Pharmacogenomics - Video
OMAHA, Neb.--(BUSINESS WIRE)--
Transgenomic, Inc. (TBIO) today reported financial results for the three and nine months ended, September 30, 2012, and provided a business update.
Third Quarter Financial Results
Net sales for the third quarter of 2012 were $7.9 million compared with $8.3 million for the same period in 2011. Despite the decline in consolidated sales, the Company realized double digit growth in its Clinical Laboratories segment, its largest business, driven by sales of its C-GAAP test, which identifies whether or not a heart disease patient will benefit from Plavix (clopidogrel) treatment, and also due to a shift in sales mix to higher priced tests. This increase was offset by a decline in the Pharmacogenomics Services segment, due to a lower volume of projects performed for our pharmaceutical clients. We also had a decline in our Diagnostic Tools segment, which had a higher percentage of its sales go to our European distribution partner at distributor prices.
Gross profit was $3.8 million or 48 percent of net sales, compared with gross profit of $4.4 million or 54 percent of net sales for the same period in 2011. The margin decline was largely due to the significantly lower margins in the Pharmacogenomics Services segment, since its costs are relatively fixed. The Clinical Laboratories segment also had a more modest decline in its gross margin, as it is making investments to improve efficiency in anticipation of the upcoming volume growth from the C-GAAP test and the recently acquired ScoliScore test.
Operating expenses were $6.2 million during the third quarter of 2012, compared with $4.9 million in the prior year. The increase was the result of a higher bad debt provision, higher non-cash stock compensation expense, higher costs related to expansion of our field sales force to support the launch of C-GAAP and ScoliScore, and higher research and development expenses.
In summary, the net loss for the third quarter of 2012 was $2.8 million or $0.04 per share compared with a net loss of $1.3 million or $0.03 per share for the third quarter of 2011.
Modified EBITDA, which is a non-GAAP measure that Transgenomic views as an appropriate and sound measure of the Company's results was a loss of $1.8 million for the third quarter of 2012 compared to income of $43,000 for the same period for 2011. A reconciliation of Net Loss to Modified EBITDA is presented below.
Cash, cash equivalents and short term investments were $8.7 million as of September 30, 2012, compared with $4.9 million as of December 31, 2011.
Nine Month Financial Results
Link:
Transgenomic Reports Third Quarter 2012 Financial Results
ScoliScore/C-GAAP Should Drive Clinical Lab Revs in 2013 By Brian Marckx, CFA
Q3 2012 RESULTS
Transgenomic (TBIO) reported financial results for Q3 ending September 30, 2012 on November 8th. Revenue fell just over 4% yoy and was well below our estimate due to relatively disappointing numbers from the Pharmacogenomics and Instruments/Diagnostics segments. While Clinical Lab revenue was dead-on with our $4.5 million estimate, the 10% yoy growth in this segment was more than offset by a very poor showing in Pharmacogenomics ($220k, -60% yoy) and Instruments ($3.2 million, -12% yoy).
As a reminder, Pharmacogenomics activity can be highly variable q-to-q, largely dependent on customer directives and not in direct control of TBIO which makes forecasting this line difficult on a short-term basis. Nonetheless Pharmacogenomics revenue in aggregate has disappointed over the first nine months of the year - which we think relates at least in part to longer than anticipated timelines (and potentially delays) of TBIO's phase III clinical trial customer(s). TBIO is still awaiting the green-light from a pharma customer to commence processing for a phase III trial - our model had assumed this work would have already commenced - we are now pushing this assumption and the related revenue back to 2013.
The quarter did have some important positive highlights, namely the ScoliScore acquisition and new collaborations with ICE COLD PCR (with NYU and Univ of Nebraska). Management also noted that C-GAAP, TBIO's Plavix response test, has seen strong physician interest and was a substantial contributor to the 10% growth in Clinical Lab revenues. ScoliScore, as we noted in our 8/9/12 Investor Note (see below), looks like a very solid addition to TBIO's Clinical Lab business and one which we think will make a meaningful top and bottom line impact as early as next year.
The collaboration with NYU's Langone Medical Center involves the use of ICE COLD PCR in the detection of mutations in the blood related to non-small cell lung cancer and response to existing a new therapies. Similar to the collaboration with the MD Anderson Cancer Center (Univ of Texas), the NYU study will focus on circulating tumor cells (CTCs) and use TBIO's CTC capture ScreenCell devices. The collaboration with the University of Nebraska Medical Center involves the use of ICE COLD PCR in the early detection of pancreatic cancer and is being funded by a $100k NIH grant awarded to TBIO which was announced in August. The project could result in a diagnostic test for early stage pancreatic cancer which is almost always fatal if not caught early.
Revenue
Q3 revenue was $7.9 million, down 4% y-o-y and $1.1 million (13%) less than our $9.0 million estimate. The difference came from a $555k variance ($220k A vs. $775k E) in Pharmacogenomics revenue and a $607k variance ($3.2 million A vs. $3.8 million E) in Instruments/Diagnostics with Clinical Lab revenue in-line with our $4.5 million estimate.
Similar to Q1 and Q2, GM came in well softer than our estimate. Q3 GM was 48% compared to our 55% estimate. Lower than expected revenue from Pharmacogenomics continues to impact GM due to the fixed laboratory costs - while this segment should be highly leverageable with growing revenue, margins will be almost non-existent at the ~$250k and lower revenue level (this quarter was $220k). Management also noted that they've made some investments related to their Clinical Lab segment to improve efficiencies in anticipation of increased sales of C-GAAP and ScoliScore which slightly impacted margins in that business in Q3. We continue to look for GM to widen with growing revenues in Pharmacogenomics, an increase in contribution from the higher margin bionconsumables (as opposed to instruments) from the Diagnostics/Tools business and potentially (depending on reimbursement) very beefy margins from ScoliScore as well as C-GAAP.
Net Income / EPS
The rest is here:
ScoliScore/C-GAAP Should Drive Clinical Lab Revs in 2013 - Analyst Blog
By Brian Marckx, CFA
Q3 2012 RESULTS
Transgenomic (OTC Markets:TBIO) reported financial results for Q3 ending September 30, 2012 on November 8th. Revenue fell just over 4% yoy and was well below our estimate due to relatively disappointing numbers from the Pharmacogenomics and Instruments/Diagnostics segments. While Clinical Lab revenue was dead-on with our $4.5 million estimate, the 10% yoy growth in this segment was more than offset by a very poor showing in Pharmacogenomics ($220k, -60% yoy) and Instruments ($3.2 million, -12% yoy).
As a reminder, Pharmacogenomics activity can be highly variable q-to-q, largely dependent on customer directives and not in direct control of TBIO which makes forecasting this line difficult on a short-term basis. Nonetheless Pharmacogenomics revenue in aggregate has disappointed over the first nine months of the year - which we think relates at least in part to longer than anticipated timelines (and potentially delays) of TBIO's phase III clinical trial customer(s). TBIO is still awaiting the green-light from a pharma customer to commence processing for a phase III trial - our model had assumed this work would have already commenced - we are now pushing this assumption and the related revenue back to 2013.
Relative to the Instruments/Diagnostics business, management noted that while they sold more instruments in the quarter compared to the year earlier period, revenue was significantly softer as the majority were sold through Menarini, their European distributor (at a lower average price point relative to the year earlier period which were mostly non-distributor sales). Going forward we continue to expect bioconsumables to be the major revenue driver of the Diagnostics business, particularly with the launch of several cancer marker kits using ICE COLD PCR which should begin to show a meaningful contribution in 2013.
The quarter did have some important positive highlights, namely the ScoliScore acquisition and new collaborations with ICE COLD PCR (with NYU and Univ of Nebraska). Management also noted that C-GAAP, TBIO's Plavix response test, has seen strong physician interest and was a substantial contributor to the 10% growth in Clinical Lab revenues. ScoliScore, as we noted in our 8/9/12 Investor Note (see below), looks like a very solid addition to TBIO's Clinical Lab business and one which we think will make a meaningful top and bottom line impact as early as next year.
The collaboration with NYU's Langone Medical Center involves the use of ICE COLD PCR in the detection of mutations in the blood related to non-small cell lung cancer and response to existing a new therapies. Similar to the collaboration with the MD Anderson Cancer Center (Univ of Texas), the NYU study will focus on circulating tumor cells (CTCs) and use TBIO's CTC capture ScreenCell devices. The collaboration with the University of Nebraska Medical Center involves the use of ICE COLD PCR in the early detection of pancreatic cancer and is being funded by a $100k NIH grant awarded to TBIO which was announced in August. The project could result in a diagnostic test for early stage pancreatic cancer which is almost always fatal if not caught early.
Revenue
Q3 revenue was $7.9 million, down 4% y-o-y and $1.1 million (13%) less than our $9.0 million estimate. The difference came from a $555k variance ($220k A vs. $775k E) in Pharmacogenomics revenue and a $607k variance ($3.2 million A vs. $3.8 million E) in Instruments/Diagnostics with Clinical Lab revenue in-line with our $4.5 million estimate.
Gross Margin
Continue reading here:
ScoliScore/C-GAAP Should Drive Clinical Lab Revs in 2013
Biomarkers For Psychiatric Disorders
ll4.me Biomarkers For Psychiatric Disorders Blood and Brain Gene Expression in Major Psychiatric Disorders: A Search for Biomarkers.- Biomarkers in Schizophrenia.- Proteomic strategies for biomarker discovery from differential expression to isoforms to pathways.- Schizophrenia Biomarkers: a means to advance the disease understanding, diagnosis and treatment.- RNA Biomarkers in Schizophrenia.- Metabolomics: a global biochemical approach to the discovery of biomarkers for psychiatric disorders.- Animal models for schizophrenia a brief overview.- Synaptoproteomics of existing and new animal models of depression.- Animal Models for Anxiety Disorders.- Animal Models of affective behaviors and drug addiction.- Neuroimaging biomarkers in schizophrenia.- Sleep EEG provides biomarkers in depression.- Strategies to identify biomarkers for depression.- Pharmacogenetics of antidepressant response.- Perspectives for an integrated biomarker approach to drug discovery and development.- Hunting for peripheral biomarkers to support drug development in psychiatry.- Biomarkers for the development of antidepressant and anxiolytic drugs.- DNA biomarkers for pharmacogenomics and personalized medicine.- Biological modeling in the discovery and validation of cognitive dysfunctions biomarkers. EAN/ISBN : 9780387792514 Publisher(s): Springer, Berlin, Springer US Discussed keywords: Neurologie Format: ePub/PDF Author(s): Turck, Chris W. Blood and Brain Gene Expression in Major Psychiatric Disorders ...From:judybruno986Views:0 0ratingsTime:00:13More inPeople Blogs
Follow this link:
Biomarkers For Psychiatric Disorders - Video
FARMINGTON, Conn., Nov. 6, 2012 /PRNewswire-iReach/ -- Four innovating life science fields to keep an eye on include blood banking, spectrometry, anticoagulants, and cell and tissue culture. Thanks to an aging population and a steep increase in healthcare expenditures among other trends, these markets are on the rise.
(Photo: http://photos.prnewswire.com/prnh/20121106/CG07120)
Global Information Inc (GII) presents four innovative life science market research reports from our premium research partner Global Industry Analysts, Inc. These global strategic business reports provide market forecasts, profile key companies and players, and review mergers, acquisitions and other strategic industry activities related to the dynamic markets for spectrometers, cell and tissue cultures, anticoagulants and blood banking.
Spectrometers and Spectrophoto/Fluorometers
Spectroscopic instruments are the swiss army knife of laboratories they perform diverse tasks such as monitoring processes, identifying compounds and elucidating chemical structures. Driven by rising sales of instrument systems by laboratories, the market for spectroscopy instruments recovered in 2010 and experienced a strong resurgence in 2011 and is project to reach $18.4 billion by the year 2018.
Developed markets such as the United States, Europe and Japan account for a predominant share of the global market for spectrometers and spectrophoto/fluorometers. Despite the continued dominance of developed regions, emerging economies specifically in Asia-Pacific, such as India and China, and Latin America are expected to offer newer opportunities owing to the different economics as well as application needs.
In the long run, demand from industries such as metals, chemicals and automotive is expected to continue driving growth in the spectroscopy market. Advancements in the areas of drug discovery and development, metabolomics, pharmacogenomics, and expanded application markets bode well for the future of spectroscopy market. Above average demand is also expected from security and defense industries; research targeted at discovery and use of new materials as well as continued growth in applications suitable for use in the life sciences market. Advanced spectrometers of the future will target the emerging demands of areas such as mineralogy, medicine, environment, pharmaceuticals and biochemistry.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/go134266-spectrometers.html
Cell/Tissue Culture Supplies
The global market for Cell/Tissue Culture Supplies is projected to reach US$5.6 billion by 2018, driven by advances in biotechnology and life science research coupled with broader range of application areas. Going forward, the market for Cell/Tissue Culture Supplies is expected to grow at an impressive pace, fueled by heightened interest in biopharmaceutical therapeutics, human and veterinary vaccine applications, and growing success of industrial biopharmaceuticals.
Continue reading here:
Global Market for Blood Banking and Blood Products Projected to reach $43 billion by 2018; Spectrometers and ...
LOS ANGELES, Nov. 5, 2012 /PRNewswire/ --Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI1 (crizotinib)2 to treat non-small-cell lung cancer ("NSCLC") patients with ALK gene rearrangements. Tumors driven by rearrangements in the ROS1 gene represent an additional 1 to 2 percent of patients who may be candidates for crizotinib therapy.3 The company will offer both fluorescence in situ hybridization ("FISH") and polymerase chain reaction ("PCR") based ROS1 translocation testing.
"We are pleased to add ROS1 to our growing test menu," said Thomas Bologna, chairman and CEO of Response Genetics. "We believe the dual option of FISH and PCR represent a unique offering and is consistent with our Leave No Stone Unturned program whereby we go to great lengths to help patients receive optimal therapy. While FISH is the technology that has been used for ROS1 to date, PCR has the advantage of providing additional information about the variant found, information that may be useful for evaluating response and resistance mechanisms.This promising new marker is now readily available to pathologists and oncologists seeking fast turnaround time and utilizes the company's proprietary methods that enable results on very small biopsies including fine needle aspirates."
ROS1 supplements the company's recently introduced Leave No Stone Unturned program, in which patients whose tumors test negative for the ALK Break Apart FISH assay receive follow-up ALK testing using the company's proprietary EML4-ALK RT-PCR-based assay at minimal additional cost. With the addition of ROS1, ordering clinicians can now make a more complete evaluation of each of their NSCLC patients as candidates for crizotinib therapy.
1 XALKORI is a registered trademark of Pfizer, Inc. 2 Bergethon et. al. "ROS1 rearrangements define a unique molecular class of lung cancers." Journal of Clinical Oncology 2012 Mar 10;30(8):863-70. Epub 2012 Jan 3. 3 Ibid
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic tests for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomics testing services of clinical-trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.
Forward-Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to continue to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, and to continue to execute on its business strategy and operations, to continue to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.
These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Read the original here:
Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
Monday
Job Search 101: Free series hosted by Christ Centered Jobs Ministry. Mondays, Nov. 5, 12, 19 and 26, 9:30 a.m.-noon, Living Word Lutheran Church, 3700 South Mason Road, Katy. Information: Selina Ponniah, selinapon@gmail.com, 281-352-4712 or Jean Marie Huntington, dbhuntington@consolidated.net, 281-693-9764.
Introduction to Microsoft Power Point: Class hosted by Leisure Learning Unlimited. 6:20-9:30 p.m., 2990 Richmond, sixth floor. Cost: $169. Information: http://www.llu.com or 713-529-4414.
Tuesday
The After Hours Network: Meeting. 6-8 p.m., Little Napoli Italian Cuisine, 6445 Westheimer. Speaker: Robert Hinsley. Topic: How to beat the credit card sharks. Cost: $15. Information: http://www.afterhoursnetwork.com.
Bio/Medical Technology Club of Houston: Monthly breakfast meeting. 7-8:30 a.m., Rotary House International, 1600 Holcombe. Speaker: Kevin Rosenblatt, M.D., Ph.D., UTHealth. Topic: Cancer Companion Diagnostics and Pharmacogenomics Testing for Predicting Patient Response to Therapeutics. Cost: $25-$40. Information: Deborah Mansfield, 713-201-4378.
Applications Principles and Intro to Windows: Class hosted by Leisure Learning Unlimited. 9:30 a.m.-5 p.m., 2990 Richmond, sixth floor. Cost: $99. Information: http://www.llu.com or 713-529-4414.
Wednesday
Services Cooperative Association - Houston CrossRoads Business Building Breakfast: 7:15-8:30 a.m., H.E.S.S. Club, 5430 Westheimer. Cost: $22-$30. Information: http://www.servicesca.org/crossroads.htm.
The Parkway Business Partners Chapter of BNI: Meeting. 7:15-9 a.m., Willow Fork Country Club, 21055 Westheimer Parkway, Katy. Speaker: Tom McCarty of Five Star Inspection Service. Information: Chris, 832-252-9413.
More:
Business calendar
Pharmacogenomics, Anticancer Drug Discovery, And Response
ll4.me Pharmacogenomics, Anticancer Drug Discovery, And Response EAN/ISBN : 9781603270885 Publisher(s): Springer, Berlin, Humana Press Format: ePub/PDF Author(s): Teicher, Beverly A. - Innocenti, Federico EAN/ISBN : 9781603270885 Publisher(s): Springer, Berlin, Humana Press Format: ePub/PDF Author(s): Teicher, Beverly A. - Innocenti, FedericoFrom:melissaforbes9865Views:0 0ratingsTime:00:11More inPeople Blogs
Go here to read the rest:
Pharmacogenomics, Anticancer Drug Discovery, And Response - Video
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Metamark Genetics, Inc., a privately held, oncology-focused molecular diagnostics company, announced today that it has closed a $13 million series B financing led by current and new private investors. The proceeds from this round will enable the company to further refine its novel, protein-based prostate cancer prognostic tests and complete final clinical validation work. The company is developing two separate prognostic tests. The first is designed to use prostate cancer biopsy tissue to help physicians more accurately determine if patients have a slow-growing or aggressive form of prostate cancer, thereby improving treatment decisions. The second is designed to predict the longer-term course of disease.
This new funding comes on the heels of Metamark successfully completing important proof-of-concept work last spring, said Kenneth Weg, Metamark co-founder and founding chairman of the board of directors. This enables us to proceed with diagnostic and drug target research at an accelerated rate and moves us closer to our goal of achieving commercialization of the Metamark prostate cancer test.
Leadership and board appointments
In conjunction with closing the financing, the company announced changes to the board of directors and the resignation of Mark Straley as president and CEO. Straley resigned to pursue other opportunities and Metamark is conducting a search for a new CEO to lead the company into commercialization and further development.
Michael Kauffman, M.D., Ph.D., joined the Metamark Genetics board of directors and will serve as interim executive director until a new company president and CEO is appointed. Kauffman was vice president of medicine and an early employee at Millennium Predictive Medicine, the diagnostics and pharmacogenomics arm of Millennium Pharmaceuticals Inc. where he co-led collaborations with Becton Dickinson and Bristol-Myers Squibb. More recently, Dr. Kauffman co-founded Karyopharm Therapeutics, a pharmaceutical company developing novel oncology drugs. He was previously chief medical officer of Proteolix Pharmaceuticals and Onyx Pharmaceuticals Inc., where he oversaw the clinical development of carfilzomib. He received his M.D. and Ph.D. from Johns Hopkins Medical School and is board certified in internal medicine.
Greg Critchfield, M.D., M.S., was appointed as lead director of the board. Dr. Critchfield has served on the Metamark board since September 2010. Previously he served as president and board member of Myriad Genetic Laboratories, Inc., the diagnostic subsidiary of Myriad Genetics, Inc., where he was responsible for building scientific, medical, and commercial capabilities and launching seven novel molecular diagnostic products across a variety of technology platforms. Prior to Myriad, he served as chief medical and science officer with responsibility for science, medicine, and innovation at Corning Clinical Laboratories, which later became Quest Diagnostics, Inc. Dr. Critchfield received a bachelor's degree in Microbiology with a minor in Chemistry from Brigham Young University, a M.D. degree from the University of Utah, and a master's degree in Biophysical Sciences at the University of Minnesota. He currently serves as CEO of Sera Prognostics, Inc., and is an independent director of a number of innovative life sciences companies.
Commenting on the leadership changes, Dr. Critchfield stated, Mark has led the company to achieve critical clinical and commercial milestones and we thank him for his contributions and wish him the very best with his future endeavors. He continued, During this time of transition, we are pleased to have Kens continued leadership on our board. He has served as board chairman since the company was formed and has been a rallying foundation for the company. We also feel fortunate to have an individual of Michaels talents and accomplishments serve in this interim leadership capacity as we complete validation of the strong clinical diagnostics foundation built by the Metamark Founders and employees.
About Metamark Genetics, Inc.
Metamark is a privately held oncology company focused on the development of molecular function-based prognostic assays for early staged cancers. The MetamarkDx Prognostic Assays under development are based on Metamarks proprietary Prognosis Determinants, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the companys website at http://www.metamarkgenetics.com.
Original post:
Metamark Genetics Completes $13 Million Series B Financing; Announces Leadership Changes
Pharmacogenetics Of Psychotropic Drugs
ll4.me Pharmacogenetics Of Psychotropic Drugs Pharmacogenetics and pharmacogenomics are areas of rapidly growing importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the findings that have already emerged. Coverage extends to antipsychotics, antidepressants, mood stabilizing, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore an essential reference for all clinicians and researchers working in this field. Publisher: Cambridge University Press Illustration: N Language: ENG Title: Pharmacogenetics of Psychotropic Drugs Pages: 00000 (Encrypted PDF) On Sale: 1998-08-28 SKU-13/ISBN: 9780521806176 Category: Medical : Pain Medicine Category: Medical : Psychiatry - General Category: Medical : Pharmacology Pharmacogenetics and pharmacogenomics are areas of rapidly growing importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practic medical, pain medicine, psychiatry, generalFrom:erintoltzViews:10 0ratingsTime:00:16More inPeople Blogs
Continued here:
Pharmacogenetics Of Psychotropic Drugs - Video
First Pass Metabolism - Pharmacology Lect 6
First Pass Metabolism: Definition and core concepts. View the rest of my pharmacology videos in order below: (1) Pharmacokinetics Core concepts: youtu.be Drug Absorption Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:1519 52ratingsTime:15:15More inEducation
Read this article:
First Pass Metabolism - Pharmacology Lect 6 - Video
Phase II Metabolism - Pharmacology Lect 8
An overview of Phase II metabolism conjugation reactions. View the rest of my pharmacology videos in order below: (1) Pharmacokinetics Core concepts: youtu.be Drug Absorption Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:780 36ratingsTime:08:28More inEducation
Read the original:
Phase II Metabolism - Pharmacology Lect 8 - Video
Phase I Metabolism - Pharmacology Lect 7
Overview of Phase I metabolism cytochrome P450 system (CYP450, P450). View the rest of my pharmacology videos in order below: (1) Pharmacokinetics Core concepts: youtu.be Drug Absorption Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:1117 25ratingsTime:06:56More inEducation
Visit link:
Phase I Metabolism - Pharmacology Lect 7 - Video
Dan Roden: "Genomes, Hype, and a Realistic Pathway to Personalized Medicine"
Watch video of the Chancellor #39;s Lecture Series, featuring a talk by Dr. Dan Roden: "Genomes, Hype, and a Realistic Pathway to Personalized Medicine" Roden is widely-recognized for his expertise in clinical, genetic, cellular, and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies. Over the past decade, he has led Vanderbilt #39;s broader efforts in pharmacogenomics discovery and implementation. Currently, he directs the Vanderbilt DNA databank, BioVU and the John A. Oates Institute for Experimental Therapeutics. Roden also serves as Principal Investigator for the Vanderbilt sites of the National Institutes of Health #39;s Pharmacogenomics Research Network and the National Human Genome Research Institute #39;s Electronic Medical Records and Genomics network. During this lecture, Roden led a conversation focused on DNA, genetic variations, and the roles they play in effecting health outcomes. Against this background, he engaged us in a relevant and riveting conversation that bunks the hype and cut right to the facts of how modern personalized medicine allows physicians to use a patient #39;s DNA to tailor the best possible treatment for various illnesses and conditions. The Chancellor #39;s Lecture Series brings to Vanderbilt and the wider Nashville community intellectuals who are shaping the world today. Each lecture -- for which reservations are not required -- is free and open to the public. To receive announcements about Chancellor Lecture Series ...From:VanderbiltUniversityViews:124 2ratingsTime:01:03:23More inEducation
Follow this link:
Dan Roden: "Genomes, Hype, and a Realistic Pathway to Personalized Medicine" - Video
Enzyme Induction - Pharmacokinetics Lect 11
Enzyme Induction, Pharmacokinetics and Drug Metabolism. View the rest of my pharmacology videos in order below: (1) What is Pharmacokinetics? ADME: youtu.be Drug Absorption Videos: (2) Drug Absorption Overview: youtu.be (3) Bioavailability: youtu.be --------- DRUG DISTRIBUTION Videos: (4) Drug Distribution Overview: youtu.be (5) Volume of Distribution: youtu.be ------------------ DRUG METABOLISM Videos: (6) First Pass Metabolism: youtu.be (7) Phase I Metabolism: youtu.be (8) Phase II Metabolism: youtu.be (9) First Order and Zero Order Kinetics: youtu.be (10) Drug Half-life: youtu.be (11) First-order elimination rate constant: youtu.be ------------------------------------------ DRUG ELIMINATION / EXCRETION (12) Drug Clearance: [not yet posted] (13) Practice problems: [not yet posted] (13) Dosage Regimens: [not yet posted] --------------------------------------------------------------------- Factors That Affect Drug Metabolism: (14) Enzyme Induction: youtu.be (15) Competitive Inhibition Overview: youtu.be (16) Competitive Inhibition of Statins: youtu.be (17) Acetaminophen toxicity (Clinical Correlate): [Not yet posted] (18) Pharmacogenomics Overview: youtu.be (19) Slow Acetylators - Pharmacogenomics: [not yet posted]From:Areo SaffarzadehViews:437 21ratingsTime:17:49More inEducation
More here:
Enzyme Induction - Pharmacokinetics Lect 11 - Video
8th ISABS Conference
We are pleased to invite you to our 8th ISABS Conference on Forensic, Anthropologic and Medical Genetics, Split, Croatia, June 24 -- 28, 2013. The conference is next in the series of biennial events organized by the International Society for Applied Biological Sciences (ISABS), a society dedicated to the promotion of applied molecular biology (www.isabs.hr) Spectacular program for 2013 will include the following topics: Forensics Genetics New perspectives in Human Forensic Molecular Biology Archaeological Genetics Genetic Geneology Forensic Genetics and Mass Catastrophes Managements Crime Scene Investigation Homeland Security Genomics in Medicine Pharmacogenomics and Drug Development Stem Cells in Medicine Gene Therapy Regenerative Medicine Mathematical Modeling in Cancer Therapy Ribosomes in Medicine The Future of Glycobilogy Together with several conference regulars, next year will bring many new and exciting names including Nobel Prize laureates Aaron Ciechanover, Robert Huber and Ada Yonath. We are pleased to inform you that the Croatian Medical Journal, the official journal of the International Society of Applied Biological Sciences, will dedicate a thematic issue to the Eighth ISABS Conference on Forensic, Anthropologic and Medical Genetics, Split, Croatia, June 24-28, 2013. The previous such special issues of CMJ (2001, 2003, 2005, 2007, 2009) were highly successful and cited. CMJ is indexed in Biosis, Current Contents/Clinical Medicine, PubMed/Medline ...From:Stipe PavelaViews:40 0ratingsTime:05:32More inScience Technology
See the original post:
8th ISABS Conference - Video